Cyclopharm (CYC.AX) Stock Price

Cyclopharm Price

CLOSED
0.56AUD-0.02 (-3.48 %)
Market closed

Revenue has compounded at 6.0% per year over the past 19 years to 27.57 M AUD. Earnings per share have declined at 11.3% per year over the last 11 years. Cyclopharm's net margin stands at -47.9%, down from -41.2% several years earlier. Cyclopharm currently offers a dividend yield of about 1.77%. The dividend has grown at 4.3% per year over the past 8 years. Analysts set a median price target of 1.53 AUD, implying 170.8% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 23% above its 52-week low.

Cyclopharm stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Cyclopharm over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Cyclopharm stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Cyclopharm's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Cyclopharm Stock Price History
DateCyclopharm Price
8/3/20260.56 AUD
7/31/20260.58 AUD
7/30/20260.58 AUD
7/29/20260.60 AUD
7/28/20260.52 AUD
7/27/20260.56 AUD
7/24/20260.56 AUD
7/23/20260.56 AUD
7/22/20260.55 AUD
7/21/20260.56 AUD
7/20/20260.57 AUD
7/17/20260.60 AUD
7/16/20260.57 AUD
7/15/20260.61 AUD
7/14/20260.49 AUD
7/13/20260.50 AUD
7/10/20260.52 AUD
7/9/20260.51 AUD
7/8/20260.46 AUD
7/7/20260.46 AUD
7/6/20260.47 AUD
7/3/20260.49 AUD
7/2/20260.50 AUD
7/1/20260.50 AUD
6/30/20260.48 AUD
6/29/20260.50 AUD
6/26/20260.50 AUD
6/25/20260.47 AUD
6/24/20260.52 AUD
6/23/20260.55 AUD
6/22/20260.53 AUD
6/19/20260.56 AUD
6/18/20260.56 AUD
6/17/20260.54 AUD
6/16/20260.55 AUD
6/15/20260.55 AUD
6/12/20260.57 AUD
6/11/20260.59 AUD
6/10/20260.59 AUD
6/9/20260.61 AUD
6/5/20260.63 AUD
6/4/20260.63 AUD
6/3/20260.66 AUD
6/2/20260.68 AUD
6/1/20260.67 AUD
5/29/20260.71 AUD
5/28/20260.70 AUD
5/27/20260.70 AUD
5/26/20260.70 AUD
5/25/20260.71 AUD
5/22/20260.73 AUD
5/21/20260.74 AUD
5/20/20260.76 AUD
5/19/20260.80 AUD
5/18/20260.81 AUD
5/15/20260.81 AUD
5/14/20260.83 AUD
5/13/20260.77 AUD
5/12/20260.80 AUD
5/11/20260.84 AUD
5/8/20260.85 AUD
5/7/20260.75 AUD
5/6/20260.74 AUD
5/5/20260.73 AUD
5/4/20260.73 AUD
5/1/20260.73 AUD
4/30/20260.73 AUD
4/29/20260.74 AUD
4/28/20260.74 AUD
4/27/20260.72 AUD
4/24/20260.70 AUD
4/23/20260.73 AUD
4/22/20260.73 AUD
4/21/20260.75 AUD
4/20/20260.76 AUD
4/17/20260.72 AUD
4/16/20260.74 AUD
4/15/20260.77 AUD
4/14/20260.78 AUD
4/13/20260.76 AUD
4/10/20260.80 AUD
4/9/20260.83 AUD
4/8/20260.81 AUD
4/7/20260.87 AUD
4/2/20260.85 AUD
3/27/20260.75 AUD
3/26/20260.75 AUD
3/25/20260.81 AUD
3/24/20260.77 AUD
3/23/20260.75 AUD
3/20/20260.72 AUD
3/19/20260.73 AUD
3/18/20260.73 AUD
3/17/20260.70 AUD
3/16/20260.68 AUD
3/13/20260.75 AUD
3/12/20260.77 AUD
3/11/20260.76 AUD
3/10/20260.73 AUD
3/9/20260.72 AUD
3/6/20260.74 AUD
3/5/20260.74 AUD
3/4/20260.77 AUD
3/3/20260.81 AUD
3/2/20260.83 AUD
2/27/20260.83 AUD
2/26/20260.83 AUD
2/25/20260.85 AUD
2/24/20260.86 AUD
2/23/20260.86 AUD
2/20/20260.85 AUD
2/19/20260.92 AUD
2/18/20260.91 AUD
2/17/20260.78 AUD
2/16/20260.81 AUD
2/13/20260.82 AUD
2/12/20260.91 AUD
2/11/20260.94 AUD
2/10/20260.94 AUD
2/9/20260.95 AUD
2/6/20260.99 AUD
2/5/20260.97 AUD
2/4/20260.99 AUD
1/30/20261.17 AUD
1/29/20261.23 AUD
1/28/20261.12 AUD
1/27/20261.05 AUD
1/23/20260.89 AUD
1/22/20260.89 AUD
1/21/20260.94 AUD
1/20/20260.94 AUD
1/19/20260.96 AUD
1/16/20260.97 AUD
1/15/20260.99 AUD
1/14/20260.98 AUD
1/13/20260.99 AUD
1/12/20261.00 AUD
1/9/20260.96 AUD
1/8/20260.98 AUD
1/7/20260.98 AUD
1/6/20260.98 AUD
1/5/20261.00 AUD
1/2/20260.99 AUD
12/30/20250.98 AUD
12/29/20250.98 AUD
12/24/20250.97 AUD
12/23/20250.97 AUD
12/22/20250.97 AUD
12/19/20250.95 AUD
12/18/20250.99 AUD
12/17/20250.96 AUD
12/16/20250.99 AUD
12/15/20251.00 AUD
12/12/20251.00 AUD
12/11/20251.00 AUD
12/10/20251.03 AUD
12/9/20251.00 AUD
12/8/20250.98 AUD
12/5/20250.95 AUD
12/4/20250.93 AUD
12/3/20250.90 AUD
12/2/20251.00 AUD
12/1/20250.96 AUD
11/28/20250.79 AUD
11/27/20250.69 AUD
11/26/20250.71 AUD
11/25/20250.68 AUD
11/24/20250.71 AUD
11/21/20250.75 AUD
11/20/20250.80 AUD
11/19/20250.79 AUD
11/18/20250.65 AUD
11/17/20250.64 AUD
11/14/20250.65 AUD
11/13/20250.65 AUD
11/12/20250.66 AUD
11/11/20250.65 AUD
11/10/20250.65 AUD
11/7/20250.64 AUD
11/6/20250.65 AUD
11/5/20250.63 AUD
11/4/20250.65 AUD
11/3/20250.64 AUD
10/31/20250.64 AUD
10/30/20250.67 AUD
10/29/20250.62 AUD
10/28/20250.66 AUD
10/27/20250.63 AUD
10/24/20250.66 AUD
10/23/20250.65 AUD
10/22/20250.70 AUD
10/21/20250.74 AUD
10/20/20250.74 AUD
10/17/20250.71 AUD
10/16/20250.76 AUD
10/15/20250.62 AUD
10/14/20250.58 AUD
10/13/20250.63 AUD
10/10/20250.68 AUD
10/9/20250.71 AUD
10/8/20250.72 AUD
10/7/20250.80 AUD
10/6/20250.87 AUD
10/3/20250.85 AUD
10/2/20250.85 AUD
10/1/20250.80 AUD
9/30/20250.81 AUD
9/29/20250.83 AUD
9/26/20250.83 AUD
9/25/20250.86 AUD
9/24/20250.84 AUD
9/23/20250.88 AUD
9/22/20250.88 AUD
9/18/20250.88 AUD
9/17/20250.90 AUD
9/16/20250.83 AUD
9/15/20250.89 AUD
9/12/20250.88 AUD
9/11/20250.78 AUD
9/10/20250.84 AUD
9/9/20250.85 AUD
9/8/20250.90 AUD
9/5/20250.88 AUD
9/4/20250.87 AUD
9/3/20250.91 AUD
9/2/20250.96 AUD
9/1/20250.98 AUD
8/29/20250.99 AUD
8/28/20251.00 AUD
8/27/20251.00 AUD
8/26/20251.01 AUD
8/25/20251.00 AUD
8/22/20250.98 AUD
8/21/20251.02 AUD
8/20/20250.96 AUD
8/19/20250.98 AUD
8/18/20251.02 AUD
8/15/20251.01 AUD
8/14/20251.00 AUD
8/13/20250.97 AUD
8/12/20250.96 AUD
8/11/20250.95 AUD
8/8/20251.01 AUD
8/7/20250.99 AUD
8/6/20251.00 AUD
Access this data via the Eulerpool API
Get Free API Key

Cyclopharm Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
17.85 M AUD
-4.52 M AUD
-5.04 M AUD
Jan 1, 2022
24.96 M AUD
-5.89 M AUD
-6.61 M AUD
Jan 1, 2023
27.77 M AUD
-8.60 M AUD
-4.70 M AUD
Jan 1, 2024
27.57 M AUD
-14.52 M AUD
-13.20 M AUD
Jan 1, 2025 (e)
32.30 M AUD
-12.66 M AUD
-8.85 M AUD
Jan 1, 2026 (e)
36.60 M AUD
-14.34 M AUD
-15.44 M AUD
Jan 1, 2027 (e)
46.20 M AUD
-18.10 M AUD
-7.20 M AUD
Jan 1, 2028 (e)
55.30 M AUD
-21.67 M AUD
-2.88 M AUD

Cyclopharm Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 8:52 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
SHARESM
2013201420152016201720182019202020212022202320242025e2026e2027e2028e
11.0012.0012.0014.0013.0013.0014.0014.0017.0024.0027.0027.0032.0036.0046.0055.00
10.009.09–16.67-7.14–7.69–21.4341.1812.50–18.5212.5027.7819.57
72.7366.6775.0071.4376.9276.9278.5771.4370.5970.8362.9662.9662.9662.9662.9662.96
8.008.009.0010.0010.0010.0011.0010.0012.0017.0017.0017.0020.1522.6728.9634.63
––2.001.00––-3.00-5.00-4.00-5.00-8.00-14.00-12.00-14.00-18.00-21.00
––16.677.14––-21.43-35.71-23.53-20.83-29.63-51.85-37.50-38.89-39.13-38.18
-9.004.004.00–-1.00–-2.00-6.00-5.00-6.00-4.00-13.00-8.00-15.00-7.00-2.00
800.00-144.44–––––200.00-16.6720.00-33.33225.00-38.4687.50-53.33-71.43
––0.010.010.010.010.010.010.010.010.01–0.010.010.01–
58.1458.3657.9059.6467.8967.9768.1276.5989.6992.1892.66102.90102.90102.90102.90102.90
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Cyclopharm generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Cyclopharm retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Cyclopharm's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Cyclopharm has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Cyclopharm's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Cyclopharm stock margins

The Cyclopharm margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cyclopharm. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cyclopharm.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
73.00 %
-37.31 %
-41.17 %
Jan 1, 2021
71.75 %
-25.30 %
-28.24 %
Jan 1, 2022
70.20 %
-23.59 %
-26.48 %
Jan 1, 2023
63.06 %
-30.97 %
-16.93 %
Jan 1, 2024
65.04 %
-52.65 %
-47.86 %
Jan 1, 2025 (e)
65.04 %
-39.18 %
-27.40 %
Jan 1, 2026 (e)
65.04 %
-39.18 %
-42.17 %
Jan 1, 2027 (e)
65.04 %
-39.18 %
-15.59 %

Cyclopharm Stock Revenue, EBIT, Earnings per Share

The Cyclopharm earnings per share therefore indicates how much revenue Cyclopharm has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.19 AUD
-0.07 AUD
-0.08 AUD
Jan 1, 2021
0.20 AUD
-0.05 AUD
-0.06 AUD
Jan 1, 2022
0.27 AUD
-0.06 AUD
-0.07 AUD
Jan 1, 2023
0.30 AUD
-0.09 AUD
-0.05 AUD
Jan 1, 2024
0.27 AUD
-0.14 AUD
-0.13 AUD
Jan 1, 2025 (e)
0.31 AUD
-0.12 AUD
-0.09 AUD
Jan 1, 2026 (e)
0.36 AUD
-0.14 AUD
-0.15 AUD
Jan 1, 2027 (e)
0.45 AUD
-0.18 AUD
-0.07 AUD

Cyclopharm business model & stock analysis

Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals.

Cyclopharm SWOT Analysis

Strengths

Cyclopharm Ltd possesses several key strengths that contribute to its success:

  • Well-established brand reputation and recognition in the market.
  • Strong portfolio of innovative and high-quality products.
  • Extensive distribution network, enabling wide market reach.
  • Robust financial performance and consistent revenue growth.

Weaknesses

Despite its strengths, Cyclopharm Ltd faces certain weaknesses that need addressing:

  • Relatively high production costs impacting profit margins.
  • Limited global presence compared to some competitors.
  • Dependency on a few key suppliers for critical raw materials.
  • Occasional product recalls affecting brand reputation.

Opportunities

Cyclopharm Ltd can seize the following opportunities to further enhance its position:

  • Expanding into emerging markets with increasing healthcare infrastructure.
  • Developing strategic partnerships and collaborations to access new technologies.
  • Growing demand for advanced diagnostic imaging solutions.
  • Investing in research and development for new product innovations.

Threats

Cyclopharm Ltd must be cautious and address the following threats to mitigate potential risks:

  • Intense competition from established multinational pharmaceutical companies.
  • Stringent government regulations and compliance requirements.
  • Economic fluctuations and currency exchange rate risks.
  • Rapidly evolving market trends and technological advancements.

Cyclopharm Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Cyclopharm historical P/E ratio, EBIT multiple, and P/S ratio

Cyclopharm annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Cyclopharm shares outstanding

The number of shares of Cyclopharm was 102.9 M in 2025. This indicates how many shares Cyclopharm is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
76.59 M Stocks
Jan 1, 2021
89.69 M Stocks
Jan 1, 2022
92.18 M Stocks
Jan 1, 2023
92.66 M Stocks
Jan 1, 2024
102.90 M Stocks
Jan 1, 2025 (e)
102.90 M Stocks
Jan 1, 2026 (e)
102.90 M Stocks
Jan 1, 2027 (e)
102.90 M Stocks

Cyclopharm stock splits

In Cyclopharm's history, there have been no stock splits.

Cyclopharm Dividend History

9 years of dividend payments

YearAnnual DividendYoY ChangePayments
20230.01AUD 0.0%2×
20220.01AUD 0.0%2×
20210.01AUD 0.0%2×
20200.01AUD 0.0%2×
20190.01AUD 0.0%2×
20180.01AUD 0.0%2×
20170.01AUD↓ 23.8%2×
20160.01AUD↑ 83.8%2×
20150.01AUD—1×

Cyclopharm dividend history and estimates

In 2025, Cyclopharm paid a dividend amounting to 0.01 AUD. Dividend means that Cyclopharm distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2019
0.01 AUD
0.00 AUD
Jan 1, 2020
0.01 AUD
0.00 AUD
Jan 1, 2021
0.01 AUD
0.00 AUD
Jan 1, 2022
0.01 AUD
0.00 AUD
Jan 1, 2023
0.01 AUD
0.00 AUD
Jan 1, 2025 (e)
0.00 AUD
0.01 AUD
Jan 1, 2026 (e)
0.00 AUD
0.01 AUD
Jan 1, 2027 (e)
0.00 AUD
0.01 AUD

Cyclopharm dividend payout ratio

In 2025, Cyclopharm had a payout ratio of 47.65%. The payout ratio indicates the percentage of the company's profits that Cyclopharm distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
-12.67 %
Jan 1, 2021
-17.79 %
Jan 1, 2022
-13.95 %
Jan 1, 2023
-19.72 %
Jan 1, 2024
47.65 %
Jan 1, 2025 (e)
47.65 %
Jan 1, 2026 (e)
60.68 %
Jan 1, 2027 (e)
51.99 %

Current Cyclopharm forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
1.53
Last Price
0.55
Currency
AUD
12M Return Potential
180.73 %
LTM Return
0 %

Cyclopharm shareholder structure

% Name
12.83878%
Anglo Australian Christian and Charitable Fund
Anglo Australian Christian and Charitable Fund
11.66431%
Regal Funds Management Pty. Ltd.
Regal Funds Management Pty. Ltd.
11.14275%
Barings Acceptance Ltd.
Barings Acceptance Ltd.
9.58929%
Australian Ethical Investment Ltd.
Australian Ethical Investment Ltd.
8.92891%
Chemical Overseas Ltd.
Chemical Overseas Ltd.
6.45738%
CVC Ltd.
CVC Ltd.

Cyclopharm Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.4%
Float Shares
-
Shares Outstanding
-

Cyclopharm Executives and Management Board

8 members · 13 % women

JM

Mr. James Mcbrayer

Chief Executive Officer, Managing Director, Executive Director, Company Secretary · since 2008

849,588.00 AUD

Management

MF

Mr. Mathew Farag

Chief Operating Officer

396,983.00 AUD
JS

Mr. Jason Smith

Chief Financial Officer

–

Board of Directors

DH

Mr. David Heaney

Independent Non-Executive Chairman of the Board

80,044.00 AUD
DA

Ms. Dianne Angus

Non-Executive Independent Director

57,489.00 AUD
KB

Mr. Kevin Barrow

Non-Executive Independent Director

21,655.00 AUD
PK

Prof. Dr. Gregory King

Non-Executive Independent Director

15,144.00 AUD
JW

Mr. John Wigglesworth

Non-Executive Director

–

Cyclopharm Supply Chain

Cyclopharm Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Siemens Healthineers
Supplier·Customer·Health Care Equipment & Supplies·DE
0.54
0.56
0.38
0.76
-0.45
—
2
HSBC Holdings
Supplier·Customer·Banks·GB
-0.03
0.41
0.47
-0.54
-0.27
—
3
CVC
Supplier·Customer·Capital Markets·AU
-0.37
-0.02
0.21
-0.39
-0.69
—

Frequently asked questions about Cyclopharm

The business model of Cyclopharm Ltd revolves around the development and commercialization of nuclear medicine products. Cyclopharm is a global leader in the manufacture and distribution of Technegas, a diagnostic imaging agent used for the detection of pulmonary embolism. With a focus on nuclear medicine, Cyclopharm carries out research, development, and production activities to offer innovative solutions for physicians and patients in need of accurate diagnoses. By leveraging their expertise in nuclear medicine, Cyclopharm aims to improve medical imaging techniques and contribute to better patient outcomes worldwide.

Cyclopharm Ltd is primarily active in the medical and healthcare industries.

The main competitors of Cyclopharm Ltd in the market include Progenics Pharmaceuticals, Curium, and Navidea Biopharmaceuticals. These companies also operate in the medical imaging industry and offer products and services that compete with Cyclopharm's offerings.

Cyclopharm Ltd is a leading global radiopharmaceutical company. Established in 1988, Cyclopharm focuses on developing and commercializing innovative nuclear medicine products. The company specializes in technetium generators, used for diagnostic imaging procedures, particularly in lung ventilation and perfusion examinations. With a strong commitment to research and development, Cyclopharm has continued to expand its product portfolio and global presence over the years. The company is headquartered in Sydney, Australia, and has a strong track record in delivering advanced solutions for the medical imaging industry. Cyclopharm Ltd has emerged as a trusted name in the field of radiopharmaceuticals, providing cutting-edge diagnostic tools for better patient care.

Cyclopharm Ltd, a leading healthcare company, has achieved several significant milestones throughout its journey. The company has successfully developed and launched innovative nuclear medicine technologies, including Technegas, a ventilation imaging agent rapidly adopted by the global medical community. Cyclopharm Ltd has established a strong international presence, with distribution networks spanning across multiple continents, allowing them to provide their life-saving products to patients worldwide. The company's commitment to research and development has yielded groundbreaking advancements in diagnostic imaging, revolutionizing the industry. Cyclopharm Ltd continues to strive for excellence, consistently delivering cutting-edge solutions and improving patient outcomes.

Cyclopharm Ltd is primarily present in Australia, New Zealand, and Canada.

Cyclopharm Ltd represents values of innovation, excellence, and patient care. The company maintains a strong corporate philosophy centered around enhancing the field of nuclear medicine through advanced radiopharmaceutical products and services. Cyclopharm Ltd is committed to delivering reliable diagnostic solutions that enable healthcare professionals to effectively diagnose and monitor various diseases. With a focus on research and development, the company strives to introduce groundbreaking technologies and therapies to improve patient outcomes. As a leader in the nuclear medicine industry, Cyclopharm Ltd continuously aims to provide cutting-edge solutions that contribute to the advancement of medical imaging and patient well-being.

Analysts currently set an average price target of 1.53 AUD for the Cyclopharm stock (median: 1.53 AUD), implying +180.7 % versus the latest price. The consensus is based on 5 analyst ratings.

Cyclopharm Analyst Price Targets 2026

5 analysts currently rate the Cyclopharm stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Cyclopharm to generate revenue of 36.60 M AUD and earnings per share of -0.15 AUD.

Cyclopharm Analyst Price Targets 2026

Converted at the current exchange rate, the Cyclopharm share trades at 0.34 EUR (0.56 AUD).

Cyclopharm Ltd is an Australian medical technology company specializing in X-ray diagnostics. The company offers innovative diagnostic solutions and services for nuclear medicine imaging and therapy planning. The company's main business model focuses on three different divisions: diagnostics, therapy planning, and research. Each division has its own products and services. For diagnostics, Cyclopharm offers Atomlab® Systems, a platform for nuclear medicine imaging that combines PET and SPECT technology. Atomlab® Systems facilitates radiologists and doctors in making critical decisions by providing detailed images of the body to help detect abnormalities and diseases. For therapy planning, Cyclopharm offers Technegas®, a technology that allows for checking lung function and perfusion to support the diagnosis of diseases such as pulmonary embolism. Technegas® is approved by the European Union and the US Food and Drug Administration (FDA) and is considered an important part of clinical practice. In addition, Cyclopharm offers a comprehensive portfolio of radioactive isotopes used in diagnostics and therapy planning. Cyclopharm's research division focuses on developing new diagnostic methods and technologies to improve nuclear medicine imaging and deliver better outcomes for patients. The company collaborates with leading academic institutions and research facilities worldwide to develop innovative diagnostic and treatment options. Cyclopharm is headquartered in Sydney, Australia, and distributes its products and services globally. The company employs approximately 100 employees and is listed on the Australian stock exchange. Cyclopharm's business model is based on offering innovative and high-quality diagnostic solutions tailored to the needs of radiologists, doctors, and patients. By combining PET and SPECT technology, Technegas technology, and an isotope portfolio, Cyclopharm has a unique position in nuclear medicine imaging. The company is also committed to sustainability and strives for environmental compatibility and safety in all aspects of its products and services. It works closely with regulatory authorities to ensure compliance with all relevant regulations and guidelines. Overall, Cyclopharm is a leading provider of diagnostic solutions and services in nuclear medicine imaging. Through innovative technology and a strong focus on research and development, the company will continue to play an important role in the industry and contribute to improving healthcare worldwide.

The expected revenue of Cyclopharm is 36.60 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Cyclopharm is -15.44 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cyclopharm is currently -3.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cyclopharm stock.

The price-to-sales ratio (P/S) of Cyclopharm is currently 1.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cyclopharm stock.

The Eulerpool Quality Score for Cyclopharm is 3/10.

The ISIN of Cyclopharm is AU000000CYC5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cyclopharm is CYC.AX. The ticker symbol is used to trade Cyclopharm shares on the stock exchange.

Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 1.77 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.01 AUD.

The current dividend yield of Cyclopharm is 1.77 %.

Cyclopharm pays a dividend, distributed in the months of , , , .

Cyclopharm paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0.01 AUD are expected. This corresponds to a dividend yield of 1.77 %.

Cyclopharm is assigned to the 'Health' sector.

To receive the latest dividend of Cyclopharm from amounting to 0.01 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Cyclopharm are distributed in AUD.

All fundamentals and in-depth analysis of Cyclopharm

Our stock analysis for Cyclopharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Cyclopharm Stock
Cyclopharm Revenue→
Cyclopharm Stock
Cyclopharm Net Income→
Cyclopharm Stock
Cyclopharm P/E→
Cyclopharm Stock
Cyclopharm P/S→
Cyclopharm Stock
Cyclopharm EBIT→
Cyclopharm Stock
Cyclopharm Dividend→
Cyclopharm Stock
Cyclopharm Directors Dealings→
Cyclopharm Stock
Cyclopharm Stocks→
Cyclopharm Stock
Cyclopharm Market capitalization→
Cyclopharm Stock
Cyclopharm Debt→
Cyclopharm Stock
Cyclopharm Liabilities→
Cyclopharm Stock
Cyclopharm Equity→
Cyclopharm Stock
Cyclopharm AAQS→
Cyclopharm Stock
Cyclopharm Employees→
Cyclopharm Stock
Cyclopharm ROE→
Cyclopharm Stock
Cyclopharm ROA→
Cyclopharm Stock
Cyclopharm ROCE→
Cyclopharm Stock
Cyclopharm News→
Cyclopharm Stock
Cyclopharm Analyst Price Targets→

Health Stocks

Cyfuse Biomedical KKCyclerion TherapeuticsCynata TherapeuticsCybinCypherpunk TechnologiesCyberdyneCytek BiosciencesCVS HealthCytodynCVS GroupCytogenCVRxAll Stocks A–Z →